A5074644543- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
- Cancer therapeutics and mechanisms
- Cancer Research and Treatments
- RNA modifications and cancer
- PARP inhibition in cancer therapy
- Chronic Myeloid Leukemia Treatments
- Myasthenia Gravis and Thymoma
- Ubiquitin and proteasome pathways
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Neuroblastoma Research and Treatments
- Pleural and Pulmonary Diseases
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Pituitary Gland Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pancreatic and Hepatic Oncology Research
- Toxin Mechanisms and Immunotoxins
- Genetic factors in colorectal cancer
Center for Cancer Research
2016-2025
National Cancer Institute
2016-2025
National Institutes of Health
2015-2024
Westchester Medical Center
2024
Mercy Clinic Neurology
2023-2024
Government Medical College
2023
Mercy Hospital
2023
National Institute of Technology Calicut
2022
Mesothelioma Applied Research Foundation
2018
American Society of Clinical Oncology
2018
Every year the American Cancer Society estimates number of new cancer cases and deaths expected in United States current compiles most recent data on incidence, mortality, survival, using National Institute (NCI) incidence Center for Health Statistics (NCHS) mortality data. Incidence death rates are age adjusted to 1970 US standard population. It is estimated that 1,284,900 will be diagnosed 555,500 people die from 2002. From 1992 1998, declined males females, while decreased among increased...
Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel medical oncology, thoracic surgery, radiation pulmonary, pathology, imaging, advocacy experts conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, prospective retrospective comparative observational studies published from 1990 through 2017. Outcomes interest...
We conducted a basket clinical trial to assess the feasibility of such design strategy and independently evaluate effects multiple targeted agents against specific molecular aberrations in histologic subtypes concurrently.We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell cancer, thymic malignancies who underwent genomic characterization oncogenic drivers. Patients were onto not-otherwise-specified arm treated standard-of-care therapies or one following five...
In patients with advanced chemotherapy-refractory mesothelioma, treatment the anti-mesothelin immunotoxin SS1P and immunosuppression pentostatin cyclophosphamide resulted in marked durable tumor regressions.
Abstract Immune checkpoint blockade (ICB) benefits only a small subset of patients with cell lung cancer (SCLC), yet the mechanisms driving benefit are poorly understood. To identify predictors clinical to ICB, we performed immunogenomic profiling tumor samples from relapsed SCLC. Tumors who derive ICB exhibit cytotoxic T-cell infiltration, high expression antigen processing and presentation machinery (APM) genes, low neuroendocrine (NE) differentiation. However, elevated Notch signaling,...
Radiation therapy is a mainstay of cancer treatment but does not always lead to complete tumor regression. Here we combine radiotherapy with blockade the 'don't-eat-me' cell-surface molecule CD47 in small cell lung (SCLC), highly metastatic form cancer. potently enhances local antitumor effects preclinical models SCLC. Notably, also stimulates off-target 'abscopal' inhibiting non-irradiated SCLC tumors mice receiving radiation. These abscopal are independent T cells require macrophages that...
Abstract Molecular subtypes of small cell lung cancer (SCLC) defined by the expression key transcription regulators have recently been proposed in lines and limited number primary tumors. The clinical biological implications neuroendocrine (NE) metastatic SCLC, extent to which they vary within between patient tumors patient-derived models is not known. We integrate histology, transcriptome, exome, treatment outcomes SCLC from a range sites, revealing complex intra- intertumoral heterogeneity...
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine cancer. Oncogenic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of amplification and phenotypic plasticity, characterized by nonneuroendocrine cell states, are not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA fluorescence in situ hybridization to find extrachromosomal (ecDNA) as a primary source oncogene driver fusions. ecDNAs bring proximity enhancer...
Abstract Purpose: Amatuximab is a chimeric monoclonal antibody to mesothelin, cell surface glycoprotein highly expressed in malignant pleural mesothelioma (MPM). On the basis of its synergy with chemotherapy preclinical studies, we evaluated antitumor activity amatuximab plus pemetrexed and cisplatin patients unresectable MPM. Experimental Design: In single-arm phase II study, (5 mg/kg) was administered on days 1 8 (500 mg/m2) (75 day 21-day cycles for up six cycles. Patients response or...
BACKGROUND The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant consisting a murine variable antibody fragment [Fv] linked PE38, truncated portion Pseudomonas exotoxin A) in combination with pemetrexed cisplatin chemotherapy‐naive patients advanced malignant pleural mesothelioma (MPM). Secondary objectives included tumor response, SS1P pharmacokinetics, serum biomarkers response....
Purpose Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that inhibition sensitizes tumors to TOP1 inhibitors. We hypothesized combination selective M6620 (previously VX-970) topotecan, inhibitor, would be tolerable active, particularly in with high replicative stress. Patients Methods This phase I study tested the topotecan 3-week cycles using 3 + dose escalation. The primary end point was identification...
CellMinerCDB provides a web-based resource (https://discover.nci.nih.gov/cellminercdb/) for integrating multiple forms of pharmacological and genomic analyses, unifying the richest cancer cell line datasets (the NCI-60, NCI-SCLC, Sanger/MGH GDSC, Broad CCLE/CTRP). enables data queries genomics gene regulatory network exploration pharmacogenomic determinants drug signatures. It leverages overlaps lines drugs across databases to examine reproducibility expand pathway analyses. We illustrate...
<h3>Importance</h3> Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies antitumor activity in this disease, but little is known about the of anti–programmed ligand (PD-L1) patients mesothelioma. <h3>Objective</h3> To assess efficacy safety avelumab a cohort previously treated <h3>Design, Setting, Participants</h3> Phase 1b open-label study (JAVELIN Solid Tumor)...
This phase I study, which to our knowledge is the first-in-human study of this kind, investigates safety, tolerability, pharmacokinetics, and clinical activity anetumab ravtansine, an antibody-drug conjugate anti-mesothelin antibody linked maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known express tumor-differentiation antigen mesothelin.This I, open-label, multicenter, dose-escalation dose-expansion ravtansine enrolled 148 adult multiple tumor types....